Tel Aviv, Feb 22, 2026, 09:47 (IST) — Market closed.
- The Tel Aviv Stock Exchange is shut on Sunday, pushing attention to Monday’s local policy decision and global cues.
- Bank of Israel’s rate call, shekel moves and a burst of U.S. tech earnings sit on the same tape.
- Teva is back in focus after fresh U.S. regulatory news tied to a long-acting schizophrenia treatment.
Tel Aviv’s stock market is closed on Sunday under its new Monday-to-Friday trading week, with investors looking straight at the Bank of Israel’s interest-rate decision due on Monday afternoon. (Clearstream)
Why it matters now is simple: rates still do most of the heavy lifting in a market dominated by banks and other rate-sensitive names. A shift in guidance can move local bond yields and the shekel, and equities tend to follow.
Outside Israel, traders will take their cues from a week led by Nvidia’s earnings as markets look for fresh evidence that AI spending is paying off — and for any wobble in risk appetite. (Reuters)
The blue-chip TA-35 index ended Friday at 4,232.11, up 0.52% on the day and about 1.1% on the week, while the broader TA-125 closed at 4,202.67, up 0.71% and roughly 0.9% on the week, according to Investing.com data. (Investing)
The currency backdrop is steady but not quiet. The dollar was around 3.119 shekels on Sunday, with the past week’s range running roughly 3.087 to 3.130 and a recent high around 3.144, Wise data showed. (Wise)
On the corporate front, Teva said the U.S. Food and Drug Administration accepted its New Drug Application — an NDA — for TEV-’749, a once-monthly long-acting injectable version of olanzapine for adults with schizophrenia. Teva and partner Medincell also flagged that there is currently no long-acting olanzapine option without an FDA Risk Evaluation and Mitigation Strategy (REMS), a safety program that can require treatment in certified settings and post-dose monitoring. “Treatment adherence remains a major challenge and unmet need,” Teva’s Eric Hughes said. (Teva Pharmaceuticals)
Teva’s Tel Aviv-listed shares last closed at 10,730 shekels versus a 10,640 previous close — a gain of about 0.85% — according to Investing.com pricing. (Investing)
Still, the week is not just about domestic rates or a single stock story. Bank earnings sensitivity to rates, exporters’ currency exposure and the tone in U.S. tech can all show up in Tel Aviv in a hurry, especially in dual-listed names.
But the risk case is sitting in plain sight. Reuters reported U.S. military planning on Iran had reached an advanced stage and President Donald Trump said he was considering limited strikes — a mix that can hit sentiment and push energy prices around. (Reuters)
